NAD+, Sirtuins, and Longevity: Separating Genuine Science from Hype
NAD+ is one of the most essential molecules in the cell - a coenzyme required for hundreds of enzymatic reactions including energy metabolism, DNA repair, and the activity of the sirtuin longevity proteins. NAD+ levels decline with age, and restoring them has extended lifespan in multiple animal models. But the human evidence is more nuanced than the supplement marketing suggests. Here is what the science actually shows.
- NAD+ is a coenzyme present in every living cell, essential for glycolysis, the TCA cycle, the electron transport chain, DNA repair via PARP enzymes, and the activity of sirtuins - a family of deacylase proteins that regulate metabolism, stress resistance, and aging across virtually every model organism studied.
- NAD+ levels decline 40 to 60 percent between young adulthood and old age, driven by increased consumption (by PARPs responding to rising DNA damage), decreased synthesis, and increased degradation by CD38 - an enzyme that rises dramatically with age and chronic inflammation.
- NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most studied NAD+ precursors. Both reliably raise blood NAD+ levels in humans in published trials. Whether blood NAD+ increases reflect meaningful tissue-level increases in critical organs - particularly the brain and heart - is less certain.
- The most powerful lifestyle activators of NAD+ pathways are exercise (activates AMPK and NAMPT, the rate-limiting enzyme in NAD+ synthesis) and caloric restriction or fasting (reduces NAD+ consumption by PARPs via reduced DNA damage). These effects are larger and more reliably tissue-level than current supplementation evidence.
- The sirtuins - SIRT1 through SIRT7 - are the primary downstream mediators of NAD+'s longevity effects. SIRT1 and SIRT3 are most relevant for longevity: SIRT1 regulates mitochondrial biogenesis, inflammation, and circadian rhythms; SIRT3 regulates mitochondrial function and the antioxidant response.
The NAD+ story is one of the most compelling in modern longevity science - and one of the most commercially exploited. The underlying biology is genuinely important: NAD+ sits at the center of cellular energy metabolism and serves as the essential substrate for the sirtuin family of enzymes, which regulate biological responses to stress, caloric availability, and aging across virtually every model organism studied. The animal evidence for NAD+ restoration in aging is compelling. The human evidence is more limited and more nuanced.1
NAD+: What It Is and What It Does
Nicotinamide adenine dinucleotide exists in oxidized (NAD+) and reduced (NADH) forms, cycling between them as electrons are transferred in metabolic reactions. As NAD+, it accepts electrons from glucose and fatty acid metabolism; as NADH, it donates them to the electron transport chain to generate ATP. This redox cycling is fundamental to cellular energy production - every cell in the body depends on it.2
Beyond its metabolic role, NAD+ serves as a substrate (consumed in the reaction, not recycled) for two critically important enzyme families: PARPs (poly-ADP-ribose polymerases), which consume NAD+ to repair DNA strand breaks, and sirtuins, which consume NAD+ to remove acetyl groups from histone and non-histone proteins, regulating gene expression, metabolism, and stress responses. When DNA damage is high (as in aging), PARPs compete aggressively with sirtuins for the available NAD+ pool, suppressing sirtuin activity precisely when it is most needed.
Why NAD+ Declines With Age
Three converging mechanisms drive the age-related decline in NAD+ levels observed across tissues in humans and animal models:3
Increased PARP activation: As DNA damage accumulates with age, PARP enzymes are chronically activated, consuming NAD+ at an accelerating rate. This creates a vicious cycle: reduced NAD+ impairs sirtuin-mediated DNA repair, leading to more damage, more PARP activation, and further NAD+ depletion.
CD38 upregulation: CD38 is an NAD+-consuming enzyme that rises dramatically with age and is further induced by chronic inflammation and senescent cell accumulation. CD38 is the dominant consumer of NAD+ in aged tissues and a primary driver of the NAD+ decline associated with aging. Compounds that inhibit CD38 - including apigenin, quercetin, and luteolin - may therefore support NAD+ levels by reducing its degradation rather than increasing its synthesis.
Reduced NAMPT activity: NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the salvage pathway that recycles nicotinamide back into NAD+. NAMPT activity declines with age and sedentary behavior, reducing the efficiency of NAD+ recycling.
The Sirtuins: NAD+'s Primary Longevity Mediators
The seven mammalian sirtuins (SIRT1-7) are deacylase enzymes that remove acetyl, succinyl, and malonyl groups from target proteins in an NAD+-dependent manner, fundamentally regulating cellular metabolism and stress responses. Their role in longevity was first established in yeast by Leonard Guarente's lab, and subsequently demonstrated across worms, flies, and mammals.4
SIRT1 is the most studied mammalian sirtuin and the primary mediator of caloric restriction's effects in mammals. It regulates mitochondrial biogenesis (via PGC-1 alpha deacetylation), circadian clock function, NF-kB-mediated inflammation, and insulin signaling. SIRT1 activity is impaired in aged tissues and in metabolic disease - both conditions associated with NAD+ depletion.
SIRT3 is the primary mitochondrial sirtuin, localized to the mitochondrial matrix where it deacetylates and activates key enzymes in the TCA cycle, fatty acid oxidation, and the antioxidant response (including manganese superoxide dismutase, the primary mitochondrial antioxidant enzyme). SIRT3 deficiency in mice accelerates aging phenotypes; SIRT3 overexpression protects against age-related metabolic dysfunction.5
"Sirtuins are sensors of the metabolic state of the cell. When energy is scarce, NAD+ rises, sirtuins activate, and the cell shifts toward maintenance and repair. This is the molecular mechanism of caloric restriction's longevity effects."
Dr. Leonard Guarente, MIT, discoverer of sirtuins' role in agingNMN vs NR: The Human Evidence
Both NMN and NR reliably raise blood NAD+ levels in published human trials. NR raises blood NAD+ in a dose-dependent manner in multiple Phase 1 and Phase 2 trials, with a well-established safety profile at doses up to 2,000mg/day.6 NMN raises blood NAD+ comparably in human trials, with the additional published finding that 12 weeks of NMN supplementation in older men improved muscle insulin sensitivity in a study by Iichiro Shimizu's group.7
The critical unresolved question is whether blood NAD+ increases reflect meaningful tissue-level increases in critical organs. Blood and skeletal muscle NAD+ increases have been demonstrated. Brain, heart, and liver NAD+ responses to oral supplementation in humans are less established, due to the difficulty of measuring tissue NAD+ non-invasively. This is not a reason to dismiss the data - it is a reason to interpret it accurately.
What Raises NAD+ Most Effectively
| Intervention | Mechanism | Evidence Quality | Practical Notes |
|---|---|---|---|
| Exercise | Activates AMPK, upregulates NAMPT | Very strong | Zone 2 most effective; tissue-level effects confirmed |
| Fasting/CR | Reduces PARP consumption, activates SIRT1 | Very strong | Effects begin within 12-16h; muscle and liver confirmed |
| NR (250-1000mg/day) | NAD+ precursor via salvage pathway | Moderate (blood NAD+ confirmed) | Well-tolerated; tissue-level less certain |
| NMN (250-1000mg/day) | NAD+ precursor, more direct route | Moderate (blood NAD+ confirmed) | Muscle insulin sensitivity data promising |
| CD38 inhibitors (apigenin, quercetin) | Reduce NAD+ degradation | Preliminary | Natural polyphenols; no human NAD+ trials yet |
| Niacin (high-dose) | Direct NAD+ precursor | Moderate | Flushing at effective doses; used in older clinical trials |
The Honest Bottom Line on NAD+ Supplementation
The biology is real, important, and well-established. NAD+ is genuinely declining with age, sirtuin activity is genuinely impaired as a result, and restoring NAD+ in aged animal models genuinely extends healthspan. NMN and NR genuinely raise blood NAD+ levels in humans and appear safe at studied doses. What does not yet exist is a human longevity RCT showing that NAD+ precursor supplementation extends healthspan or lifespan.8 This is a gap in the evidence, not a reason to dismiss the entire framework.
The practical recommendation: prioritize the lifestyle interventions with confirmed tissue-level effects (exercise, fasting) as the foundation. Consider NMN or NR at 300 to 500mg/day as a reasonable adjunct for adults over 45 who have optimized lifestyle first, with realistic expectations that they are investing in plausible biology rather than proven longevity extension.
References
- 1Verdin E. "NAD+ in aging, metabolism, and neurodegeneration." Science. 2015;350(6265):1208-1213. [PubMed]
- 2Yoshino J, et al. "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." Cell Metabolism. 2018;27(3):513-528. [PubMed]
- 3Camacho-Pereira J, et al. "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism." Cell Metabolism. 2016. [PubMed]
- 4Haigis MC, Guarente LP. "Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction." Genes Dev. 2006;20(21):2913-2921. [PubMed]
- 5Ahn BH, et al. "A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis." PNAS. 2008;105(38):14447-14452. [PubMed]
- 6Trammel SA, et al. "Nicotinamide riboside is uniquely and orally bioavailable in healthy humans." Nature Communications. 2016;7:12948. [PubMed]
- 7Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229. [PubMed]
- 8Rajman L, et al. "Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence." Cell Metabolism. 2018;27(3):529-547. [PubMed]